Reported promising safety and preliminary efficacy data for REC-617, an oral CDK7 inhibitor, and met primary endpoints and ...

Recursion Pharmaceuticals (NasdaqGS:RXRX) recently announced a $500 million Follow-on Equity Offering and revealed mixed earnings results for Q4 2024, which showed declining quarterly sales and ...

Q4 2024 Earnings Call Transcript February 28, 2025 Recursion Pharmaceuticals, Inc. misses on earnings expectations. Reported ...

Recursion Pharmaceuticals is a leader in TechBio with potential to bring in $200M in near-term milestones and $20B in future ...

Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. It is decoding biology by integrating technological ...

Recursion Pharmaceuticals (NASDAQ:RXRX – Get Free Report) had its target price dropped by Leerink Partners from $7.00 to ...

Shares of Nvidia-backed Recursion Pharmaceuticals Inc. (RXRX) ended Friday lower, extending weekly losses past 21% after ...

Gain insights into Recursion Pharmaceuticals' Q4 2024 earnings call. Discover clinical advancements, key partnerships, and strategic plans for 2025.

Plus: A shift in bird flu strategy, a new vaccine for meningococcal disease, a new AI genomics model from Nvidia and more.

Welcome everybody to Recursion's Earnings Call. I'm Chris Gibson, Co-Founder and CEO, and I'm excited to take you through Recursions 2024, 2025 and the time ahead. So with that we'll jump into the ...

Reports Q4 revenue $4.55M vs. $10.9M last year. “In 2024, Recursion made a transformative leap with the largest TechBio merger in history, ...

Recursion Pharmaceuticals shares were down 7% to $7.12 after the company reported a fourth-quarter loss that was wider than analysts expected.